Skip to main content
Clinical Trials/NCT06602986
NCT06602986Not yet recruitingNot Applicable

Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma

Pak Emirates Military Hospital2 sites in 1 country96 target enrollmentStarted: October 12, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
96
Locations
2
Primary Endpoint
Measuring the density of Iodine in Lipiodol depositions: Detecting an Invisible Residual Tumor after Conventional Transarterial Chemoembolization for Hepatocellular carcinoma

Study Overview

Brief Summary

ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up computed tomography (CT) scans Study Design: Prospective observational interventional study Place and Duration of Study: Interventional Radiology department of Armed Forces Institute of Radiology and Imaging (AFIRI) from April 2023-March 2024 Methodology: 96 patients undergoing conventional TACE were included in the study and followed up for residual tumor or tumor free status assessment using density measurement for iodine depositions using CT scan analysis and compared with gold standard digital subtraction angiography (DSA). Primary variables measured were comparison of enhancement scores between those with a residual tumor versus tumor free as well as the volume of iodine depositions in the arterial and venous phase between both groups. Sensitivity and specificity of the CT scan in assessing tumor diagnosis was compared with the gold standard digital subtraction angiography.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
16 Years to 60 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Clinical diagnosis of HCC disease
  • Must be able to swallow tablets

Exclusion Criteria

  • Insulin dependent diabetes
  • Thyroid disease

Outcomes

Primary Outcomes

Measuring the density of Iodine in Lipiodol depositions: Detecting an Invisible Residual Tumor after Conventional Transarterial Chemoembolization for Hepatocellular carcinoma

Time Frame: 9 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Pak Emirates Military Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

DR.Talha Arshad

Professor Radiology

Pak Emirates Military Hospital

Study Sites (2)

Loading locations...

Similar Trials